Ramucirumab, A Second-Line Option For Patients With Hepatocellular Carcinoma: A Review Of The Evidence

De Luca, E; Marino, D; Di Maio, M

CANCER MANAGEMENT AND RESEARCH, 2020; 12 (): 3721

Abstract

Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer and predominantly develops in patients with liver cirrhosis. In patients with......

Full Text Link